Total
0
Shares
  • Biopharmaceutical company Opthea (OPT) has announced the pricing of its initial public offering (IPO) on the Nasdaq
  • Over 8.5 million American Depositary Shares (ADS), representing over 68.5 million ordinary shares will be priced at USS$13.50 (roughly A$19.18) per ADS, before underwriting discounts and commissions
  • The biotech stock inked its plans to list on Nasdaq under the ticker code "OPT", in late August - claiming it would support product development and clinical trials
  • Opthea expects to raise US$128.2 million (roughly A$182.09 million) from the IPO
  • The company also plans to grant the underwriters a 30-day option to purchase up to an additional 1,425,000 ADSs
  • The ADSs have begun trading on the Nasdaq Global Select Market and, as of October 19, Opthea's ADSs were trading for $13.15
  • Opthea ended the day trading 2.92 per cent lower on the ASX, with shares closing at $2.33

Opthea (OPT) has announced the pricing of its initial public offering (IPO) in the United States.

Earlier this month, Opthea launched its proposed IPO of American Depositary Shares (ADS) on the Nasdaq.

Each ADS will represent eight of the company's ordinary shares which are listed and, once the IPO is completed, Opthea will continue to trade on the ASX under "OPT".

A total of 8,563,300 ADSs, representing 68,506,400 ordinary shares, will be priced at US$13.50 (roughly A$19.18) per ADS, before underwriting discounts and commissions.

Further, Opthea offered and sold to certain investors pre-funded warrants to buy 936,700 ADSs at a public offering price of US$13.49999 per pre-funded warrant.

The biotech stock inked its plans to list on Nasdaq under the ticker code "OPT", in late August - claiming any offering and listing of ADSs on the American stock exchange would support product development and clinical trials.

When it first detailed its IPO plans, Opthea hoped to raise US$160 million (roughly A$227.4 million) from the IPO. However, the company now expects to raise US$128.2 million (roughly A$182.09 million).

The company also plans to grant the underwriters a 30-day option to purchase up to an additional 1,425,000 ADSs at the IPO price per ADS less underwriting discounts and commissions.

The ADSs have begun trading on the Nasdaq Global Select Market and, as of October 19, Opthea's ADSs were trading for $13.15.

Opthea ended the day trading 2.92 per cent lower on the ASX, with shares closing at $2.33.


Subscribe


OPT by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Founder & CEO, John Kelly - The Market Herald

" Atomo Diagnostics (ASX:AT1) ends Q2 FY21 with $24.7M in cash

Atomo Diagnostics (AT1) has released its quarterly report for the December 2020 quarter which it closed off with a healthy cash balance of
4DMedical (ASX:4DX) - CEO, Andreas Fouras - The Market Herald

" 4DMedical (ASX:4DX) to trial software in California

Medical tech company 4DMedical (4DX) has secured the first U.S. clinical pilot of its XV Lung Ventilation Analysis Software (XV LVAS).
Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial

" Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial

Little Green Pharma (LGP) has been selected as a primary supplier of medicinal cannabis oils for a national trial in France.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) advances phase two efti study for COVID-19 patients

Immutep (IMM) has announced its phase two Eftilagimod Alpha Treatment COVID (EAT COVID) study will advance with enrolment towards the randomised portion.